tbuckley/cabot-search huggingface dataset:
FLUKE INFECTIONS AND SNAILS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Marriages
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Once Upon a Time . . .
Authors: Teri A. Reynolds
Journal: JAMA (2003)

WAS A WIDE screen that kept a row of yellowing Reader's Digests from sliding off the windowsill.On afternoons when it was too hot to go outside, I read "Laughter, the Best Medicine" and "Humor in Uniform," but what kept me up at night were "All in a Day's Work" and "Drama in Real Life."That adults used stories to make it through a Day's Work, that Real Life was full of Drama, made me yearn for my future.And for a day filled with Work, Life, and Drama, medicine is hard to beat.But whence the stories?Certainly, patients tell us stories; we demand them: What happened?When?How?And then we tell these tales again and again."This is a 55-year-old woman who presents with . . ." is our "Once upon a time . . ."-no less formulaic, and no less infinite in its narrative potential.But our doctor stories, whether we write them down or not, are not the same ones patients bring.They are reaction, analysis, diagnosis, invention, strategy-what we do when faced with a patient's narrative.That days are full of events is inevitable; that they may be filled with stories depends on how we navigate.Stories, and the narrative mode in general, constitute an outlook, a strategic meaning-making.The difference between a string of events and the tale taken home at the end of the day is that we deem this particular series of events worthy of a second thought, a moment of reflection, worthy of the telling-we allow to this day's work, the accumulation of meaning beyond habit.The ability to take in someone's story, to track and contextualize the meaning of a term-what does this patient mean when he says painful, when she says dizzy, when he says weak-is only part of the job.We are readers when we try to understand what has happened to our patients.We are writers when we try to understand what has happened to our selves.In this issue, Jonathan Auten shows us the way a single finding-"A left pupil, fixed and dilated"-yields events of 50 years ago, while Kimberly Mulcahy-Hawes' narrator tells us more than she realizes.Michael McWilliams wonders if this is the end, while Michael Hope struggles with knowing more of the story than his patient does.And, finally, when his patient can't fill in the blanks, Boris Veysman tells himself a story.
Carbon tetrachloride exposure during anticoagulant therapy. Dangerous enhancement of hypoprothrombinemic effect
Authors: E. F. Luton
Journal: JAMA (1965)

IT IS generally known that caution is necessary in the initiation of anticoagulant therapy in patients who are known to have kidney or liver dysfunction. The purpose of this report is to add the caution that anyone on a regimen of anticoagulant therapy should assiduously avoid exposure to carbon tetrachloride and other hepatotoxic and nephrotoxic drugs. That minimal exposure to carbon tetrachloride which might not produce apparent illness in others can lead to serious hypoprothrombinemia in patients on a regimen of anticoagulants is indicated by events in the experience that is described. <h3>Report of a Case</h3> The 59-year-old white man was admitted to the hospital on April 20, 1965. He had been treated for arteriosclerotic heart disease and angina pectoris since the age of 37, when he had the first of several known heart attacks. He had been taking bishydroxycoumarin (Dicumarol) since his last known infarction in 1960. During this
Book Review McMinn's Interactive Clinical Anatomy CD-ROM. By Peter H. Abrahams. System needed: Multimedia IBM PC or compatible computer, with 8 MB RAM. St. Louis, Mosby, 1997. $59.95 (MAC or Windows). 0-7234-2253-2 (MAC); 0-7234-2186-2 (Windows). Imaging Atlas of Human Anatomy CD-ROM (Version 2.0). By Jamie Weir and Peter H. Abrahams. System needed: Multimedia IBM PC or compatible computer, with at least 8 MB RAM. (Also available for Macintosh System 7.0 or higher, with at least 4 MB RAM.) St. …
Authors: Raphael Udassin
Journal: New England Journal of Medicine (1997)
Ethanol feeding of micropigs alters methionine metabolism and increases hepatocellular apoptosis and proliferation
Authors: C HALSTED
Journal: Hepatology (1996)

Chronic alcoholism is associated with increased cancer risk that may be related to ethanol-induced alterations in methionine and deoxynucleotide metabolism. These metabolic relationships were studied in micropigs fed diets for 12 months that contained 40% ethanol or cornstarch control with adequate folate. Ethanol feeding altered methionine metabolism without changing mean terminal liver folate levels. After initial equilibration to diet, ethanol feeding significantly increased monthly serum homocysteine levels while reducing serum methionine levels over the time course of the experiment. After 12 months, hepatic methionine synthase activity and the ratio of S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) were significantly reduced in ethanol-fed animals, whereas the ratio of liver deoxyuridine triphosphate (dUTP) to deoxythymidine triphosphate (dTTP) was increased and correlated inversely with methionine synthase activity. These findings were associated with increased frequency of hepatocytes with apoptotic bodies and positivity for proliferating cell nuclear antigen (PCNA) in livers from ethanol-fed minipigs. These studies suggest that chronic ethanol feeding perturbs methionine metabolism by impairment of methionine synthase activity, resulting in deoxynucleoside triphosphate (dNTP) imbalance, increased apoptosis, and regenerative proliferation. These biochemical alterations may provide a promoting environment for carcinogenesis during long-term ethanol exposure.
Deutsche Zeitschrift für Nervenheilkunde, Berlin
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LIMITATIONS OF ORGANOTHERAPY
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LET THE PRESCRIBER KNOW.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
Authors: D. Mavroudis, E. Saloustros, N. Malamos, S. Kakolyris, I. Boukovinas, P. Papakotoulas, N. Kentepozidis, N. Ziras, V. Georgoulias
Journal: Annals of Oncology (2020)
Ultrastructural, Cellular, and Clinical Features of the Immotile-Cilia Syndrome
Authors: J Palmblad
Journal: Annual Review of Medicine (1984)

Postpartum depression (PPD) is common, disabling, and treatable. The strongest risk factor is a history of mood or anxiety disorder, especially having active symptoms during pregnancy. As PPD is one of the most common complications of childbirth, it is ...Read More
Instructions for Authors
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nitric oxide is not involved in hepatocyte killing by neutrophils activated by N-formyl-methionyl-leucyl-phenylalanine or phorbol myristate acetate in vitro
Authors: J Wagner
Journal: Hepatology (1996)

Polymorphonuclear leukocytes (PMNS) have been implicated as cellular mediators of hepatic injury in models of inflammation in vivo. In vitro, hepatocyte killing by activated PMNs is mediated in part by proteases, but the role of nitric oxide is unknown. NO is produced by PMNs and hepatocytes and can act either to damage or protect in various models of toxicity. Therefore, we tested the hypothesis that NO is important in PMN-mediated hepatocyte killing in vitro. Freshly isolated hepatocytes from rat liver and PMNs elicited from rat peritoneum were cultured together or alone for 16 hours. Both cell types spontaneously released NO, estimated as its stable breakdown product, nitrite. Accumulation of nitrite in medium from hepatocyte cultures was augmented threefold by incubation with L-arginine and was completely inhibited by treatment with the nitric oxide synthase (NOS) inhibitor NG-methyl-L-arginine (NMA). Nitrite release in PMN cultures was unaffected by L-arginine addition and only partially inhibited by NMA. In PMN: hepatocyte cocultures (10:1), accumulation of nitrite was additive relative to cells cultured separately. Incubation with NMA blocked nitrite production completely in cocultures, whereas L-arginine caused a two-fold increase in nitrite. Addition of PMN stimulants, N-formyl-methionyl-leucyl-phenylalanine (FMLP), or phorbol myristate acetate (PMA), caused increased release of alanine aminotransferase (ALT) activity into medium from hepatocytes cultured with PMNs but not from hepatocytes cultured alone; this indicated that injury to hepatocytes was due to activated PMNS. However, neither FMLP nor PMA significantly altered nitrite release from cocultures. Despite the alterations in NO production induced by addition of NMA or L-arginine, neither agent altered the release of ALT from hepatocytes in coculture with activated PMNs. Thus, PMNs and hepatocytes provided NO in vitro, but neither suppression nor elevation of NO production affected PMN-mediated hepatocyte killing. Accordingly, NO is not involved in the mechanisms by which FMLP-or PMA-stimulated PMNs mediate hepatocyte injury in vitro. (Hepatology 1996 Apr;23(4):803-10)
Phase I trial of weekly and every-three-weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).
Authors: V. D. Guardiola Amado, A. J. Montero, A. Ferrell, A. M. Flores, M. Vulfovich, M. D. Pegram, P. W. Benedetto, C. S. Rocha Lima, J. R. Merchan
Journal: Journal of Clinical Oncology (2010)

e13516 Background: S is a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic/antiproliferative properties. Ix is a cytotoxic microtubule-stabilizing semisynthetic epothilone also containing antiproliferative and antiangiogenic effects. IX and S combination may be synergistic, since S may increase delivery of Ix to the tumor by inducing vascular normalization, and the anti-angiogenic effects of S may be enhanced by Ix through HIF-1α regulation. Methods: Patients (pts) with advanced STs were enrolled in a phase I, dose-escalation study to assess safety, pharmacokinetics (PK), angiogenesis biomarkers (ABM) and to determine the recommended phase II dose. Eligibility criteria: age ≥ 18, ≤ 4 prior systemic therapies (tx), performance status (PS) 0-2, measurable/evaluable disease and good organ function. Treatment schedules: A (weekly Ix, 3 out of 4-weeks cycle): starting dose: 7.5 mg/m2 IV (1A), 15 mg/m2 IV (2A) and 20 mg/m2 IV (3A). Schedule B (every 3 weeks): starting dose 20 mg/m2 IV (1B), 30 mg/m2 IV (2B) and 40 mg/m2 IV (3B). In both schedules, S was given continuously starting on day 8 of cycle 1 at 37.5 mg PO per day. Pts were treated in a standard 3 + 3 design with dose-limiting toxicities (DLTs) assessed in the first cycle. Results: 18 pts enrolled to date, 17 are evaluable for toxicity and 14 for efficacy. Baseline characteristics: median age: 62 (49-78); sex male/females: 11/7; most frequent histologies: colorectal (CRC)/ pancreas/ prostate: 10/2/2; median PS: 1; median of prior tx: 3. No DLTs were observed in cohorts 1A, 2A, 1B and 2B. Two pts have experienced DLTs in cohort 3A: Grade (gr) 3 DVT/gr 4 hematological adverse events (AEs), and cohort 3B: gr 4 mucositis/gr 3 dehydration. Other gr 3/4 AEs (not DLTs): neutropenia (6), anemia (5), fatigue (5), lymphopenia (3), thrombocytopenia (2) and neuropathy (2). Best responses: 2 PR, 5 SD and 7 PD. The PRs and most cases of SD were observed in heavily pretreated CRC pts. Conclusions: So far, the combination of Ix and S appears to have acceptable toxicity and shows promising activity. Enrollment in dose-level 3A and 3B is ongoing. PK and ABM analysis are underway. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb, Pfizer Pfizer Bristol-Myers Squibb, Pfizer
TCT-104 One-Year Clinical Outcomes Following Open Transatrial Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification
Authors: Michael Brener, Mohanad Hamandi, Estee Hong, Alejandro Pizano, Morgan Harloff, Evan Garner, Abdallah El Sabbagh, Ryan Kaple, David Deaton, Ashequl Islam, Ramesh Veeragandham, Vinayak Bapat, Omar Khalique, Yuming Ning, Paul Kurlansky, Tamim Nazif, Susheel Kodali, Martin Leon, Michael Borger, Raymond Lee, Keshav Kohli, Ajit Yoganathan, Mayra Guerrero, James Davies, Kyle Eudailey, Tsuyoshi Kaneko, Tom Nguyen, Hyde Russell, Robert Smith, Isaac George
Journal: Journal of the American College of Cardiology (2021)
Specialty Abstracts
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BIOFEEDBACK TRAINING IN PATIENTS WITH ADVANCED HEART FAILURE
Authors: Dana L. Frank, Matthew Baumann, Michael Liebenstein, Lamees Khorshid, Gregory J. Bolwell, Elizabeth F. Grossman, Jerome Kiffer, Wai Hong Tang, James Young, Randall Starling, Michael G. McKee, Christine Moravec
Journal: Journal of the American College of Cardiology (2012)
HIV Testing, Counseling, and Prophylaxis After Sexual Assault-Reply
Authors: Zita Lazzarini
Journal: JAMA (1994)

<h3>In Reply.</h3> —Our working group was acutely aware that our proposed policy for limited compulsory testing of the accused would become a lightning rod for discussion. We also believed that testing the accused was not the major focus of the policy, and therefore, the overwhelming burden of our original report and our article in<i>JAMA</i>focused on other means of alleviating the physical and psychological harm to survivors of sexual assault; specifically, that all survivors should receive prompt medical attention; comprehensive counseling about the potential sequelae of sexual assault; voluntary testing for sexually transmitted diseases, HIV, and pregnancy; and treatment, where appropriate. Dr Herbert and colleagues focus their comments almost exclusively on testing the accused and claim that the policy would have a differential effect on communities of color. The existence of racial bias in the criminal justice system is clear. However, these criticisms should be directed toward the system
BERLIN LETTER.
Authors: None H. R. B.
Journal: JAMA (1885)

Berlin, Jan. 28, 1885. At a meeting of the Physiological Society, the Director of the chemical laboratory of the Physiological Institute, stated that he had discovered a new element in the pancreatic juice which he called<i>Adenin</i>. It belongs to the same group as guanine and exanthine. Its chemical formula is C<sub>5</sub>H<sub>5</sub>N<sub>5</sub>. He utilized 42 litres of a watery pancreatic extract in finding it. With water of hydration it forms long, needle-form crystals. It dehydrates when exposed to the atmosphere. With the various acids it forms salts. <h3>A CASE OF OVARIOTOMY IN A PATIENT WITH HYSTERICAL HEMIANÆSTHESIA.</h3> I am indebted to Dr. L. Landau for the details of this most interesting case. I had the pleasure of seeing the patient at his office a few days ago, and could personally verify the points of the paper published by himself and Dr. E. Remak on this